Atypical bronchial carcinoid (ABC): recurrence-free survival after resection and analysis of therapeutic interventions
Level: Level 2
Launch date: 1 March 2023
Principle investigators: Eric BAUDIN
- Most bronchial carcinoids are diagnosed at stage I-II. Typical carcinoids (TC) represent 90% of this population. R0 resection of the tumor is achieved in 95% of cases.
- The recurrence rate mainly depends on the WHO classification and the TNM.
- The recurrence rate is higher in atypical carcinoids (AC): between 5 and 35% at 5 years.
- Unmet need: current studies which have analysed the post-operative follow-up of patients with atypical carcinoids are mainly retrospective and non-standardized in terms of imaging follow-up, questioning the current relapse figures, timing, and locations.
- Finally, the guideline does not recommend routine adjuvant treatment but a case-by-case discussion, mainly in atypical N-positive carcinoids.
- Future indication of adjuvant therapy may benefit from this kind of information.
- A randomised trial is not feasible in this setting due to the rarity of atypical carcinoids.
- Prospectively evaluation of recurrence-free survival at 5 and 10 years of patients with localized AC who benefit from a curative R0 resection
- Define of the anatomical sites of recurrence, the temporality, and the diagnostic methods
- Define prognostic factors for RFS, including Ki67 in the WHO classification
- Median RFS and OS
- Analyse the types of interventions and results (new R0 Status)
- Assess the prognostic role of local EBRT therapeutic intervention (vs no local intervention)
- Assess the prognostic role of systemic interventions (vs no systemic intervention) for atypical bronchial carcinoids
- Analyse the molecular profile and its added prognostic value according to the proposal of Alcala et al Nat Com 2019 (ancillary study)
- Atypical bronchial carcinoid histologically proven ,2015 WHO classification.
- Stage I-III UICC 2019
- R0 surgery < 6 months
- Patient ≥ 18 year old
- Standardized follow-up according to ESMO 2020 guidelines
- Patient who has agreed to participates.
Publication rules: Every participating institution will have 1 (co)-authorship, further participating persons of the same institution will be listed in the acknowledgement. If the number of co-authors has to be limited to a journals policy, the order will be determined according to the patient numbers recruited.
- The first author is the chairperson or PI of the study group of the study (designer/methodologist of the study).
- The second author is the best recruiter in terms of numbers and quality or the co-main author (if not the PI of the study).
- Subsequent author hierarchy is dependent on quality/quantity of recruitment/methodologist.
- The last author is the second chairperson/PI of the study (if among best recruiter).
E. Baudin from Gustave Roussy, who coordinates the study, will be shared senior author.